Genzyme/Sanofi-Aventis
On February 16 2011, Genzyme Corporation (Nasdaq: GENZ) confirmed a definitive agreement to be acquired by Sanofi-aventis (NYSE: SNY) for $74.00 per share in cash, or approximately $20.1 billion, plus one Contingent Value Right.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
-
Transgene Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
-
Transgene Announces its Invesment in ElsaLys Biotech, a New Antibody Company Created by Former Executives
-
Russell Reynolds Associates Adds Sofie Qiao to San Francisco Office and Max Zuckerman to the Palo Alto Office
-
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
-
Sanofi Relies on Axway to Future-Proof their Infrastructure and Reduce Operational Costs through Global Consolidation
-
89 Degrees Names Bill Peña Vice President of Technology Services
-
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
-
The start-up ElsaLys Biotech, a new player in the therapeutic monoclonal antibody arena, announces the first round of financing with Transgene and Sofimac Partners
-
OvaScience Reports First Quarter Fiscal 2013 Financial Results
-
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
-
Third Rock Ventures Expands and Strengthens Team
-
Parkinson's Therapeutics Reviewed by NeuroPerspective
-
Sanofi: Q1 2013 business EPS(1) impacted by exclusivity losses in prior year
-
First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivus’ Board at the 2013 Annual Meeting
-
NextBio Announces Translational Medicine Partnership with Sanofi
-
Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
-
Burrill Securities Launches Institutional Breakthrough Series
-
Transgene: Promising Final Data from the Phase 2 HCVac Trial of TG4040 Presented at EASL 2013
-
Transgene Presents Promising Pre-Clinical Data on TG1050 to Treat Chronic HBV at EASL 2013
-
J.D. Power and Associates Reports: Evidence that Relationship Marketing Still Matters in Oncology Pharmaceutical Sales
-
Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study
-
CEL-SCI Corporation Provides Update on Phase III Clinical Trial
-
U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
-
Transgene : First Quarter 2013 Financial Report
-
89 Degrees: Overview of US Loyalty Programs
-
Cubist Pharmaceuticals Reports First Quarter 2013 Financial Results
-
Genzyme Convenes 13th European Fabry Disease Roundtable
-
Veracyte Announces That New Study Suggests The Number Of Patients At Risk For Unnecessary Thyroid Surgery Is Likely On The Rise
-
Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
-
Algeta ASA : Hilde Furberg and Paolo Pucci elected as new members of Algeta's Board of Directors
-
Amarantus Announces Preclinical Development Timeline for MANF Therapeutic
-
Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic Hepatitis B and C at EASL 2013
-
Surveyed U.S. Neurologists Would Prescribe Biogen Idec's Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
-
Genzyme’s Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis
-
NextBio and Genophen Form Partnership Aimed at Applying Genomics to Personalized Disease Prevention and Wellness
-
Verastem Reports Year-End 2012 Financial Results
-
89 Degrees to Present at Demandware XChange with Clients Fila and Crabtree & Evelyn
-
Sanofi (SNY), Transgene Enter Long-Term Immunotherapy Development
-
Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments
-
Sanofi's (SNY) Genzyme Receives Positive CHMP AUBAGIO as MS Treatment
-
Sanofi (SNY) Unit Issues Encouraging Update for First-Year of LEMTRADA Phase III in MS
-
ZALTRAP® (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
-
Isis (ISIS), Genzyme (SNY) Receive FDA Approval for KYNAMRO NDA
-
Sanofi's (SNY) Genzyme sBLA for LEMTRADA Accepted by FDA
-
Alnylam (ALNY) Plans to End 2012 With $225 Million in Cash, Provides Goals
-
Stocks Crossing 50-Day SMA 12/14: (ISIS) (GOL) (SNE) Above; (QCOM) (ARIA) (PAY) Below
-
Genzyme (SNY), Isis Pharma (ISIS) Receive Negative Opinion from CHMP Over KYNAMRO
-
Sanofi's (SNY) Genzyme Receives EC Approval for Thyrogen
-
Sanofi's (SNY) Genzyme Receives Approval for AUBAGIO in Australia
-
Alnylam (ALNY), Genzyme (SNY) Enter RNAi Development for ATTR Solution in Asia
